VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Down 37.1% in November

VYNE Therapeutics Inc. (NASDAQ:VYNE) was the target of a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 64,300 shares, a decline of 37.1% from the November 15th total of 102,200 shares. Based on an average daily volume of 81,800 shares, the days-to-cover ratio is presently 0.8 days. Approximately 0.5% of the shares of the company are short sold.

Institutional Trading of VYNE Therapeutics

An institutional investor recently bought a new position in VYNE Therapeutics stock. Lynx1 Capital Management LP bought a new position in VYNE Therapeutics Inc. (NASDAQ:VYNE) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics makes up about 0.0% of Lynx1 Capital Management LP’s holdings, making the stock its 17th biggest holding. Lynx1 Capital Management LP owned approximately 0.11% of VYNE Therapeutics at the end of the most recent quarter. 83.78% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. BTIG Research initiated coverage on shares of VYNE Therapeutics in a research note on Monday, November 18th. They issued a “buy” rating and a $8.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $5.75 price objective on shares of VYNE Therapeutics in a research note on Friday, November 8th.

VYNE Therapeutics Stock Performance

Shares of NASDAQ:VYNE opened at $2.40 on Friday. The company has a market cap of $35.40 million, a PE ratio of -2.79 and a beta of 1.37. The firm has a 50 day simple moving average of $2.62 and a 200 day simple moving average of $2.20. VYNE Therapeutics has a 52 week low of $1.57 and a 52 week high of $3.43.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.